8-K: Co-Diagnostics Partners with ReadyGo for Blood-Based Testing

Co-Diagnostics and ReadyGo Diagnostics are collaborating to evaluate blood-based molecular testing at the point of need, initially focusing on decentralized Ebola detection.

Summary

• Co-Diagnostics (Co-Dx) and ReadyGo Diagnostics are collaborating to assess the integration of ReadyGo's GoCollect sample preparation technology with Co-Dx's PCR platform for blood-based molecular testing.
• The initial focus of this collaboration is on decentralized Ebola virus detection and outbreak response.
• This partnership aims to extend the Co-Dx PCR platform beyond current swab-based testing to include bloodborne pathogens like HIV and hepatitis B and C.
• The companies are evaluating the workflow compatibility of ReadyGo's GoCollect system, which prepares capillary blood samples and inactivates viruses, with the Co-Dx PCR platform for point-of-need molecular detection.
• Feasibility work has commenced, with Co-Dx receiving ReadyGo materials and devices for evaluation.
• A press conference and webcast were scheduled for September 16, 2026, at 10:30 a.m. ET to discuss the collaboration.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, indicating strategic expansion and potential new market entry, though significant development and regulatory hurdles remain.

Positives

• Potential to expand the Co-Dx PCR platform's capabilities to blood-based testing, opening new market segments.
• Initial focus on Ebola detection addresses a critical public health need, particularly in decentralized settings.
• ReadyGo's GoCollect technology offers integrated sample preparation and virus inactivation, enhancing safety and efficiency.
• The collaboration builds on Co-Dx's prior proof-of-concept work with plasma samples.
• Successful integration could significantly broaden the range of diseases addressable by the Co-Dx platform, including HIV and hepatitis B and C.

Negatives

• Compatibility between the Co-Dx PCR platform and ReadyGo's GoCollect technology has not yet been established and is the subject of ongoing feasibility work.
• There is no assurance that the evaluation will be successful or result in a commercially available product.
• The Co-Dx PCR platform has not yet been cleared or authorized by the FDA and is subject to regulatory review.
• Each new application (e.g., HIV, hepatitis B/C) will require separate development, validation, and regulatory authorization.

Risks

• Risks that feasibility or compatibility studies may not produce successful or timely results.
• Risks that the collaboration may be modified, delayed, or terminated, or may not result in a commercially available product.
• Risks related to the ability of Co-Dx and ReadyGo to successfully integrate their respective technologies.
• Risks related to regulatory review by authorities required for a successful commercial launch.
• Risks associated with the performance, reliability, and market acceptance of the Co-Dx PCR platform.
• Risks associated with dependence on third parties, suppliers, collaborators, and distribution partners.
• Risks related to competition, technological change, and intellectual property protection.

Future Outlook

The future outlook hinges on the successful evaluation and integration of ReadyGo's sample preparation technology with the Co-Dx PCR platform. If successful, it could significantly broaden the platform's applications beyond current swab-based testing to include bloodborne pathogens like HIV and hepatitis B and C, representing a substantial expansion of the commercial opportunity. However, significant development, validation, and regulatory hurdles must be overcome, and there is no guarantee of a commercially available product.

Management Comments

• "From the beginning, our objective has been to make molecular testing accessible to patients in settings with limited laboratory infrastructure. Preparing a blood sample for testing in those settings is an important part of that challenge, and ReadyGo brings technology that we believe could help us address it."
• "This work with ReadyGo builds on our earlier work with plasma as we evaluate a practical blood-based testing workflow for the Co-Dx PCR platform. While Ebola is our initial focus, we believe the longer-term significance is the potential to expand the platform into additional applications, including HIV and hepatitis B and C. There are development and validation efforts ahead, but success could substantially broaden the range of diseases we can address and the commercial opportunity for the platform."
• "We designed GoCollect for places where a laboratory isnt an option, where a sample either gets tested nearby or it doesnt get tested at all. GoCollect takes sample collection and preparation into the field, and works seamlessly with platforms such as Co-Dx to create a complete sample-to-result molecular testing solution."
• "Both technologies were designed around the same need, making high-quality molecular diagnostics practical outside conventional laboratory settings. This work will demonstrate how effectively they can operate together in the field."

Industry Context

StockSavvy.ai notes that this collaboration aligns with the growing trend in the diagnostics industry towards decentralized testing and point-of-care solutions, particularly for infectious diseases. The focus on blood-based testing for pathogens like Ebola, HIV, and hepatitis B/C taps into significant and expanding market segments that require rapid and accessible diagnostic capabilities, especially in resource-limited settings or during outbreak scenarios.

Stakeholder Impact

• Shareholders: Potential for increased market share and revenue if the collaboration leads to successful product development and commercialization, but also carries risks associated with development and regulatory hurdles.
• Patients: Potential for improved access to critical diagnostic testing, especially in remote or resource-limited areas, leading to faster diagnosis and treatment.
• Public Health Organizations: Enhanced capabilities for rapid detection and response to infectious disease outbreaks like Ebola.
• Healthcare Providers: Opportunity for more efficient and timely diagnostic workflows at the point of care.

Next Steps

• Conduct feasibility work to evaluate the compatibility and workflow integration of the Co-Dx PCR platform and ReadyGo's GoCollect technology.
• Assess the potential for blood-based molecular testing at the point of need, starting with Ebola detection.
• Explore the expansion of the Co-Dx PCR platform to include applications for HIV and hepatitis B and C.
• Undergo necessary development, validation, and regulatory authorization for any new applications.

Key Dates

Recommendation

The collaboration presents a promising avenue for expanding Co-Diagnostics' platform capabilities into new, potentially lucrative markets, particularly for bloodborne pathogens. However, the early stage of the partnership, the unproven compatibility of the technologies, and the significant regulatory hurdles for the Co-Dx platform necessitate a cautious approach. While the potential upside is considerable, the inherent risks and the lack of established revenue streams from this specific initiative warrant a 'hold' recommendation until further progress and regulatory clarity are achieved.

Keywords

molecular diagnostics, point-of-need testing, Ebola detection, bloodborne pathogens, PCR platform, sample preparation, decentralized testing, ReadyGo Diagnostics